Johnson & Johnson’s consumer products business clocked another quarter of flat sales growth on an operational basis, prompting CEO Alex Gorsky to stress patience while saying he has prioritized the return of recalled OTC brands to the marketplace.
J&J reported worldwide consumer sales of $3.62 billion in the second quarter, up 0.6% operationally but down 5.2% with the effects of currency exchange. The McNeil Consumer Healthcare division...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?